trimetazidine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Trimetazidine is a drug sold under many brand names for angina pectoris. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves the heart muscle's ability to use glucose as a fuel by inhibiting its use of fatty acid metabolism. It has become controversial for its use as a performance-enhancing drug, with several scandals involving its use erupting at successive Olympic games.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride | trimetazidine | trimetazidine dihydrochloride | trimetazidine hcl | trimetazidine hydrochloride | vastarel | vastarel mr

Organizations (43)

Research & Development (43)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (30)

Approved Indications (1)


 

Angina Pectoris

Experimental Indications - Clinical Trial Phases 1-4 (30)


 

Acute Kidney Injury (Phase 4)

Acute-On-Chronic Liver Failure (Phase 1)

Amyotrophic Lateral Sclerosis (Phase 2)

Angina Pectoris ()

Angina, Unstable (Phase 4)

Blood Platelet Disorders (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Cardiomyopathy, Hypertrophic (Phase 2)

Cardiotoxicity (Phase 2/Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

COVID-19 (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Cardiomyopathies (Phase 2)

Diabetic Nephropathies (Phase 2)

Heart Diseases (Phase 4)

Heart Failure (Phase 1)

Heart Failure, Diastolic (Phase 4)

Hypertension, Pulmonary (Phase 2/Phase 3)

Medicine, Chinese Traditional (Phase 4)

Microcirculation (Phase 4)

Motor Neuron Disease (Phase 2)

Myocardium (Phase 2)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pathology (Phase 4)

Percutaneous Coronary Intervention (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Vascular Resistance (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 30
  • # of Trial Organizations: 43

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue